Prioritize Biomarkers to Explore in Clinical Development
Champions Oncology excels at high throughput, cost-effective PDX screens. Performing gene differential analysis, global mutational analysis and pathway mapping, our bioinformatics staff team can help identify biomarkers of response and or resistance.
More than 80% of the models in the Champions Oncology TumorGraft database are available for these types of studies.
Models can be selected based on tumor type, or on a targeted molecular anomaly, or both to make faster go/no-go decision on the clinical advancement of agents.